StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
StageZero Life Sciences Ltd (SZLSF) - Total Liabilities
Latest total liabilities as of September 2024: $11.71 Million USD
Based on the latest financial reports, StageZero Life Sciences Ltd (SZLSF) has total liabilities worth $11.71 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
StageZero Life Sciences Ltd - Total Liabilities Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
StageZero Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of StageZero Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Point of Care Nano-Technology Inc
PINK:PCNT
|
USA | $145.95K |
|
QuiaPEG Pharmaceuticals Holding AB
ST:QUIA
|
Sweden | Skr8.81 Million |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
USA | $28.59 Million |
|
XMax Inc.
NASDAQ:XWIN
|
USA | $4.70 Million |
|
Regenbogen AG
F:RGB
|
Germany | €24.18 Million |
Liability Composition Analysis (1998–2022)
This chart breaks down StageZero Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 20.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how StageZero Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual total liabilities of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $8.20 Million | +4.06% |
| 2021-12-31 | $7.88 Million | -19.06% |
| 2020-12-31 | $9.74 Million | +50.88% |
| 2019-12-31 | $6.46 Million | -11.83% |
| 2018-12-31 | $7.32 Million | +28.26% |
| 2017-12-31 | $5.71 Million | -30.12% |
| 2016-12-31 | $8.17 Million | +248.50% |
| 2015-12-31 | $2.34 Million | +202.04% |
| 2014-12-31 | $776.12K | -37.93% |
| 2013-12-31 | $1.25 Million | -74.84% |
| 2012-12-31 | $4.97 Million | +13.10% |
| 2011-12-31 | $4.39 Million | -10.48% |
| 2010-12-31 | $4.91 Million | +26.84% |
| 2009-12-31 | $3.87 Million | -9.14% |
| 2008-12-31 | $4.26 Million | -18.45% |
| 2007-12-31 | $5.22 Million | +216.39% |
| 2006-12-31 | $1.65 Million | -42.02% |
| 2005-12-31 | $2.85 Million | -47.82% |
| 2004-12-31 | $5.46 Million | +914.42% |
| 2003-12-31 | $537.81K | +53.92% |
| 2002-12-31 | $349.42K | +333.38% |
| 2000-12-31 | $80.63K | -87.53% |
| 1999-12-31 | $646.52K | +22536.41% |
| 1998-12-31 | $2.86K | -- |